

From: [Tom Heffernan](#)
To: [AGO - High Cost Prescription Drugs](#)
Cc: [Irene Idnani](#); [SM-NCL-IBFinance](#); [Caitlin Fee](#)
Subject: VT Pharmaceutical Cost Transparency - Altor BioScience, LLC - Anktiva Launch Reporting
Date: Friday, April 26, 2024 6:10:43 PM

Some people who received this message don't often get email from theffernan@federalcompliancesolutions.com. [Learn why this is important](#)

EXTERNAL SENDER: Do not open attachments or click on links unless you recognize and trust the sender.

Greetings,

On behalf of Altor BioScience, LLC, and in compliance with House Bill S 92, please find details of Anktiva's notice of introduction to the market below.

Manufacturer	NDC 11	Drug Name	Commercial Launch Date
Altor BioScience, LLC	81481-0803-01	Anktiva 400 mcg/0.4 mL, single-dose vial	4/25/2024

Please confirm receipt of this submission and respond with any questions or concerns.

Regards,

Tom Heffernan

Tom Heffernan
Manager

Federal Compliance Solutions LLC
Direct: (484) 767-5327
Email: theffernan@FederalComplianceSolutions.com